Oligodendrocytes-the myelin-forming cells of the central nervous system-can be regenerated during adulthood. In adults, new oligodendrocytes originate from oligodendrocyte progenitor cells (OPCs), but also from neural stem cells (NSCs). Although several factors supporting oligodendrocyte production have been characterized, the mechanisms underlying the generation of adult oligodendrocytes are largely unknown. Here we show that genetic inactivation of SIRT1, a protein deacetylase implicated in energy metabolism, increases the production of new OPCs in the adult mouse brain, in part by acting in NSCs. New OPCs produced following SIRT1 inactivation differentiate normally, generating fully myelinating oligodendrocytes. Remarkably, SIRT1 inactivation ameliorates remyelination and delays paralysis in mouse models of demyelinating injuries. SIRT1 inactivation leads to the upregulation of genes involved in cell metabolism and growth factor signalling, in particular PDGF receptor α (PDGFRα). Oligodendrocyte expansion following SIRT1 inactivation is mediated at least in part by AKT and p38 MAPK-signalling molecules downstream of PDGFRα. The identification of drug-targetable enzymes that regulate oligodendrocyte regeneration in adults could facilitate the development of therapies for demyelinating injuries and diseases, such as multiple sclerosis.
In the adult brain, oligodendrocytes can be generated from OPCs or from NSCs (refs [1] [2] [3] [4] [5] [6] . Factors involved in oligodendrocyte production have been identified [6] [7] [8] [9] [10] [11] , but the molecular basis of adult oligodendrocyte generation is mostly undefined. Emerging evidence suggests a role for lysine deacetylation in oligodendrocyte differentiation 12, 13 , raising the possibility that lysine deacetylation also affects OPC expansion. Several members of the sirtuin family (SIRTs) are NAD + -dependent deacetylases, which connect stress stimuli and energy metabolism to lysine deacetylation 14 , making them appealing candidates for mediating oligodendrocyte regeneration 1, 15 . Although SIRT2-a cytoplasmic sirtuin-has been shown to inhibit postnatal oligodendrocyte differentiation 13 , the role of other NAD + -dependent deacetylases in oligodendrocyte differentiation or regeneration has not been examined.
SIRT1-a nuclear sirtuin-is upregulated in a mouse model of multiple sclerosis in regions of inflammation 16 , raising the possibility that the SIRT1 protein participates in the regulation of adult oligodendrocytes. SIRT1 has been extensively studied in the context of energy metabolism [17] [18] [19] [20] [21] [22] [23] [24] [25] , neurodegenerative diseases [26] [27] [28] [29] and memory 30, 31 .
SIRT1 is important in terminally differentiated cells, including neurons, in which it promotes survival and synaptic plasticity [30] [31] [32] [33] [34] . Emerging evidence suggests a role for SIRT1 in embryonic stem cells [35] [36] [37] , embryonic neural stem and progenitor cell fate determination 16, 38 and in other tissue-specific stem cells 39, 40 . However, whether and how SIRT1 regulates the function of adult NSCs and more committed progenitors originating from these cells-in particular OPCs-has not been explored. Here we report that SIRT1 inactivation in adult NSCs leads to OPC expansion in vitro and in vivo, and improves demyelinating injuries in vivo. OPC expansion following SIRT1 inactivation is mediated at least in part by activation of AKT and p38 MAPK signalling.
RESULTS

SIRT1 is expressed in adult NSCs and neural progenitors
Immunostaining with an antibody against SIRT1 revealed that the SIRT1 protein is expressed in the nucleus of adult NSCs and neural progenitors in primary cultures ( Fig. 1a and Supplementary Fig. S1a ). In vivo, SIRT1 protein is expressed-albeit at low levels-in both adult NSC niches: the subventricular zone (SVZ) and the dentate gyrus of the hippocampus ( S1e ). Thus, although SIRT1 is not highly expressed in NSC niches in vivo, it is most consistently found in proliferating cells within these niches, suggesting that SIRT1 might play an important role in these proliferating cells.
Inducible inactivation of SIRT1 in adult NSCs and neural progenitors expands the oligodendrocyte lineage
To determine the function of SIRT1 in adult NSCs and neural progenitors, we generated an inducible SIRT1 knockout mouse in which SIRT1 can be selectively inactivated in NSCs and neural progenitors in adults. To this end, we crossed mice in which exon 4 of the Sirt1 gene is flanked by loxP sites (Sirt1 lox/lox ) with NestinCreER T2 - [41] [42] [43] [44] (NestinCreER), which express a tamoxifen-inducible form of Cre (CreER) in adult NSCs and neural progenitors (Fig. 2a) . We verified that the NestinCreER T2 -IRES-hPLAP transgene was indeed expressed in the SVZ NSC niche, but not in other regions of the brain such as the striatum, septum and corpus collosum ( Supplementary Fig. S2a ). The protein product of the Sirt1 gene lacking exon 4 has no deacetylase activity and mice with germline homozygous deletion of exon 4 are phenotypically similar to Sirt1 −/− mice 45 . To trace the progeny of adult NSCs and neural progenitors in which SIRT1 is inactivated, we crossed NestinCreER;Sirt1 lox/lox mice with mice carrying a double fluorescent
IRES-hPLAP transgenic mice
Cre reporter gene (mT/mG) in which Cre recombination leads to deletion of a membrane-targeted tomato fluorescent protein (mTFP) and expression of a membrane-targeted green fluorescent protein 46 (mGFP; Fig. 2a and Supplementary Fig. S2e,f) . We confirmed that the NestinCreER;Sirt1 lox/lox mouse line allowed the specific deletion of the full-length SIRT1 protein in adult NSCs and neural progenitors when mice were injected with tamoxifen ( Supplementary Fig. S2b,d) , with no deletion from other brain regions ( Supplementary Fig. S2c,d ). We also verified that there was negligible Cre activity when mice were injected with vehicle ( Supplementary Fig. S2e,f) .
To determine the consequences of the inducible inactivation of SIRT1 in adult NSCs and neural progenitors, we injected NestinCreER;mT/mG;Sirt1 lox/lox and control NestinCreER;mT/mG mice with tamoxifen and analysed brain sections 16 h or 10 days later (Fig. 2a) . Sixteen hours after tamoxifen injection, only the NSC niches (SVZ and dentate gyrus) began expressing mGFP (Fig. 2a) , confirming that Cre-mediated deletion occurs specifically in adult brain regions containing NSCs and neural progenitors. In contrast, 10 days after tamoxifen injection, a larger number of mGFP-positive cells were observed in the SVZ (Fig. 2a) and mGFP-positive cells were also found in areas adjacent to the SVZ, including the striatum and septum (Fig. 2a,b) , suggesting that cells generated from NSC niches have migrated to these regions. The striatum and the septum are known to contain a relatively large population of OPCs that can give rise to mature oligodendrocytes 6, 47 . We tested the possibility that SIRT1 inactivation might affect cells in the OPC lineage. Notably, the striatum and septum of NestinCreER;mT/mG;Sirt1 lox/lox mice injected with tamoxifen contained a greater density of mGFP-positive cells when compared with control NestinCreER;mT/mG mice injected with tamoxifen ( Fig. 2b,c) .
A proportion of these GFP-positive cells co-expressed OLIG2, a marker of the oligodendrocyte lineage (Fig. 2c) , suggesting that SIRT1 inactivation in NSCs and neural progenitors increases the production of OPCs in the adult brain. This increase in cells of the oligodendrocyte lineage was not at the expense of other cell types because there was also an increase in the number of cells that are derived from NSCs and neural progenitors in vivo, such as astrocytes and olfactory bulb neuroblasts (Fig. 2e,f) brains. (e) Deletion of active SIRT1 in adult NSCs and neural progenitors leads to greater production of GFAP-positive NSC and neural progenitor progeny in the surrounding NSC niche. Mean ± s.e.m. of 4 independent cohorts of 2 mice per genotype for each cohort, except one in which there were 3 control mice (n = 4). Two-tailed, paired Student's t -test, striatum, * P = 0.0282; septum, * P = 0.0144. Arrowheads point to cells co-expressing mGFP and GFAP. (f) Deletion of active SIRT1 in adult NSCs and neural progenitors enhances the area in the olfactory bulb (OB) covered by mGFP fluorescence 10 days after tamoxifen injection. Mean ± s.e.m. of n = 3 NestinCreER;mT/mG and n = 4 NestinCreER;mT/mG;Sirt1 lox/lox mice. Two-tailed, unpaired Student's t -test, * P = 0.01. Tam, tamoxifen. All scale bars, 50 µm.
the generation of neural cell pools in the brain, including OPCs. Importantly, these genetic studies complement and extend viral lineage tracing studies 5, 6 and underscore that a substantial fraction of OPCs are generated from NSCs and neural progenitors under basal conditions in the adult wild-type brain, even in the absence of demyelinating injuries.
Brain-specific inactivation of SIRT1 increases the population of proliferating NSCs and OPCs
Chronic inactivation of SIRT1 in NSCs and neural progenitors from early development using NestinCre;Sirt1 lox/lox mice ( Fig. 3a and Supplementary Fig. S3a,b ) also resulted in a greater number of S3f,g ), indicative of a homeostatic control of the production of new cells under basal conditions. In the rest of this study, we focused on OPCs generated following SIRT1 inactivation because of the importance of these cells in myelination and the largely uncharacterized regulation of adult OPC generation.
SIRT1 inactivation does not alter the differentiation and myelination potential of oligodendrocytes
We investigated whether OPCs lacking active SIRT1 could generate fully differentiated oligodendrocytes. Importantly, inducible inactivation of lox/lox and NestinCre;Sirt1 lox/lox 8-week-old mice were differentiated for 7 days by growth factor removal and addition of 1% FBS after the first passage and immunostained 7 days for the mature oligodendrocyte marker MBP. Images are representative of MBP-positive cells at day 7 of differentiation. Mean±s.e.m. of 6 independent experiments. Two-tailed, unpaired Student's t -test, * P = 0.0398. Scale bars, 50 µm (b,d).
SIRT1 in adult NSCs and neural progenitors on tamoxifen injection of NestinCreER;mT/mG;Sirt1
lox/lox mice produced mGFP-positive cells in the striatum and septum that exhibited morphologies characteristic of myelinating oligodendrocytes (Fig. 2d) , consistent with the notion that NSCs and neural progenitors lacking active SIRT1 can give rise to mature, fully myelinating oligodendrocytes. In culture, NSCs and neural progenitors from NestinCre;Sirt1 lox/lox mice produced cells positive for the immature oligodendrocyte marker O4 when placed in differentiation conditions for 2, 4 and 7 days (Fig. 4a,b) . In contrast, NSCs and neural progenitors from NestinCre;Sirt1 lox/lox mice did not exhibit significant differences in the production of neurons and astrocytes on differentiation ( Supplementary Fig. S4c ), indicating that SIRT1 inactivation has a relatively specific effect on oligodendrocyte generation, at least in vitro. Interestingly, the SIRT1-specific inhibitor EX-527 also increased the production of O4-positive oligodendrocytes in NSC and neural progenitor cultures after 7 days of differentiation (Fig. 4c) . OPCs lacking active SIRT1 could generate normal oligodendrocytes: immature oligodendrocytes that formed without active SIRT1 had morphologies similar to those from control cultures ( Supplementary Fig. S4d ). Furthermore, NestinCre;Sirt1 lox/lox NSC and neural progenitor cultures also gave rise to cells expressing myelin basic protein (MBP), a marker for mature, myelinating oligodendrocytes ( Fig. 4a,d ). Finally, postnatal OPCs isolated from NestinCre;Sirt1 lox/lox mice had normal morphologies and did not exhibit a change in differentiation ability in vitro ( Supplementary Fig. S5 ). Overall, these findings indicate that SIRT1 inactivation results in an increase in the generation of normal myelinating oligodendrocytes both in vivo and in culture.
SIRT1 inactivation enhances remyelination upon demyelinating injuries and delays onset of paralysis in a chronic model of demyelination
The production of oligodendrocytes could be particularly helpful in demyelination diseases or injuries. We first investigated the remyelination ability of mice lacking active SIRT1 following lysolecithin-induced demyelination of the corpus callosum. We found that 14 days after focal injection of lysolecithin into the corpus callosum, mice lacking active SIRT1 in the brain exhibited higher levels of remyelination in the region of injection when compared with control mice (Fig. 5) . These results indicate that OPCs lacking SIRT1 can form normal oligodendrocytes following injury in the adult brain. We then examined whether SIRT1 inactivation in the brain affected the phenotype of mice with chronic experimental autoimmune encephalomyelitis (EAE), an established mouse model of multiple sclerosis [48] [49] [50] . Remarkably, NestinCre;Sirt1 lox/lox mice were initially protected against the onset of paralysis in MOG -induced chronic EAE when compared with control Sirt1 lox/lox mice (Fig. 6 ).
These data are compatible with the possibility that proliferating OPCs in NestinCre;Sirt1 lox/lox brains might help remyelinate EAE-induced demyelinating lesions, although SIRT1 inactivation may also minimize axonal damage or reduce astrogliosis. Together, these data indicate that SIRT1 inactivation in the nervous system enhances the rate of remyelination on demyelinating injury and minimizes the severity of clinical symptoms in a mouse model of multiple sclerosis.
SIRT1 inactivation in adult NSCs and neural progenitors leads to the upregulation of genes involved in metabolism, protein translation and growth factor signalling
To gain insight into the molecular mechanisms underlying the expansion of OPCs in the absence of SIRT1, we assessed the Table S1 ). A significant proportion of the genes upregulated in the absence of active SIRT1 encoded proteins with functions related to growth factor signalling (for example, platelet-derived growth factor receptor α (Pdgfrα)), cell metabolism (for example, cytochrome c oxidase subunit VIIc (Cox7c), pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), acyl-coA dehydrogenase, long chain (Acadl)) and protein translation (for example, ribosomal protein large and small subunits (Rpl13, Rpl15, Rpl21, Rps2 and Rps8); Fig. 7a,b and Supplementary Table S1 ). These findings raise the possibility that SIRT1 inactivation affects growth factor signalling, cellular metabolism and protein translation, which in turn may impact OPC expansion. These data are consistent with the observation that oligodendrocytes have a greater metabolic rate when compared with other neural cells 1, 51 . In contrast, genes downregulated in the absence of active SIRT1 were involved in neurogenesis and neuronal function ( Supplementary Fig. S6 and Table S1 ), suggesting that neuronal function may be altered in the absence of SIRT1, as has been observed in previous studies 30, 31 . To identify SIRT1-regulated pathways that could mediate the effect of SIRT1 on OPC expansion, we focused on the top upregulated genes in NestinCre;Sirt1 lox/lox NSCs and neural progenitors (Fig. 7a ). Among these top upregulated genes is Pdgfrα, a known regulator of OPC proliferation and function 9,10,52,53 , raising the possibility that SIRT1 may regulate OPCs by affecting PDGFRα signalling. We confirmed that SIRT1 inactivation results in increased Pdgfrα expression in NSCs and neural progenitors by reverse transcription followed by quantitative PCR (RT-qPCR; Fig. 7c ). This effect was relatively specific to Pdgfrα as lack of active SIRT1 did not affect the expression of genes encoding other tyrosine kinase receptors (Egfr, TrkC and Fgfr1; Fig. 7c and Supplementary Fig. S7a ). These results suggest that SIRT1 normally serves to repress Pdgfrα expression in NSCs and neural progenitors.
The increase in Pdgfrα messenger RNA levels could be an indirect consequence of SIRT1 deletion. To determine whether SIRT1 inactivation affects Pdgfrα expression in a direct manner, we examined the chromatin state at the Pdgfrα gene locus following SIRT1 deletion. SIRT1 has been shown to deacetylate acetylated Lys 9 of histone 3 (H3K9Ac) and acetylated Lys 16 of histone H4 (H4K16Ac; ref. 54) . Chromatin immunoprecipitation (ChIP) showed a twofold enrichment of H3K9Ac at the promoter of Pdgfrα in cultured adult NSCs and neural progenitors from NestinCre;Sirt1 lox/lox mice when compared with NSCs and neural progenitors from control mice (Fig. 7d) . In contrast, SIRT1 inactivation in NSCs and neural progenitors did not affect H4K16Ac or global H3K9 acetylation ( Fig. 7d and Supplementary Fig. S7b,c) . This finding suggests that SIRT1 normally catalyses H3K9 deacetylation at the Pdgfrα promoter, thereby repressing the transcription of Pdgfrα, although it is possible that SIRT1 also deacetylates transcription factors that bind in the regulatory regions of the Pdgfrα gene. These findings are also consistent with the notion that SIRT1 inactivation directly leads to increased production of PDGFRα, which could in turn help support the expansion of OPCs.
Inhibition of p38MAPK and AKT signalling reduces the production of oligodendrocytes from NSCs and neural progenitors lacking active SIRT1
We examined whether PDGFRα signalling could mediate the SIRT1-dependent increase in oligodendrocyte number in NSC and neural progenitor cultures. PDGFRα stimulation is known to elicit a number of signalling pathways, including p38 MAPK, p44/p42 MAPK, AKT and mTOR-S6K (refs 55-57). Immunoblotting with phospho-specific antibodies against the active forms of these protein kinases or their substrates revealed that loss of active SIRT1 leads to increased phospho-p38 MAPK and phospho-AKT levels in adult NSCs and neural progenitors in vitro ( Fig. 8a and Supplementary Fig. S8 ). In contrast, SIRT1 inactivation did not result in consistent changes in the phosphorylation of p44/42 MAPK or p70 S6 kinase, a target of mTOR ( Fig. 8a and Supplementary Fig. S8 ). These results indicate that lack of active SIRT1 leads to p38 MAPK and AKT pathway activation. We investigated whether the p38 MAPK and AKT pathways were required for adult OPC expansion due to SIRT1 inactivation. Inhibition of either p38 MAPK signalling with the inhibitor SB202190 or phosphatidylinositol-3-OH kinase (PI(3)K) signalling with the inhibitor LY294002 significantly decreased the production of cells positive for the oligodendrocyte marker O4 in NestinCre;Sirt1 lox/lox cultures after induction of differentiation (Fig. 8b ). An independent inhibitor of p38 MAPK (SB203580) and a direct inhibitor of AKT (MK-2206) also reduced the formation of oligodendrocytes in NestinCre;Sirt1 lox/lox cultures after induction of differentiation (Fig. 8b) , reinforcing the notion that the p38 MAPK and AKT signalling pathways are critical for the expansion of the oligodendrocyte lineage. In contrast, inhibition of the p44/42 MAPK pathway with U0126 compound had no effect on the production of O4-positive cells lox/lox and Sirt1 lox/lox NSCs and neural progenitor isolated from 8-week-old mice. Heat map represents a subset of genes upregulated in the absence of active SIRT1 that was selected on the basis of a false discovery rate of less than 0.001%. Numbers 1-3 designate independent biological experiments. Colours represent the Z score of the robust multi-array analysis-normalized expression level for each gene (red is high expression; blue is low expression). Asterisk highlights Pdgfrα, a gene important for OPC proliferation and maintenance 9, 10, 52, 53 . (b) Genes upregulated following SIRT1 inactivation are significantly over-represented in biological processes related to metabolism and ribosomal biology. Genes differentially regulated by SIRT1 were selected on the basis of a false discovery rate of less than 1% and analysed using PANTHER and Ingenuity Pathway Analysis (IPA). Canonical pathways significantly over-represented in the genes upregulated following following SIRT1 inactivation, indicating that p44/p42 MAPK activity is dispensable for OPC proliferation/maintenance in these cultures (Fig. 8b) . These results suggest that SIRT1 inactivation promotes the expansion of the OPC pool at least in part by leading to the activation of the p38 MAPK and AKT signalling pathways. We propose that SIRT1 inactivation in NSCs and neural progenitors leads to increased H3K9Ac at the Pdgfrα promoter, which would lead to elevated Pdgfrα expression, thereby allowing the activation of the AKT and p38 MAPK pathways. As both signalling pathways have been shown to regulate postnatal OPC proliferation/survival 55, 58 , the activation of the AKT and p38 MAPK pathways following SIRT1 inactivation could help support the expansion of OPCs from adult NSCs. OPCs generated following SIRT1 inactivation retain their capacity to terminally differentiate into myelinating oligodendrocytes, which raises the possibility that manipulating SIRT1 expression or activity or downstream PDGFRα-p38 MAPK and AKT pathways could lox / lox adult mice. Antibodies specific against phosphorylated forms of AKT, p38 MAPK, p44/42 MAPK and p70 S6 kinase were used. Antibodies specific against total proteins were used as loading controls. FL, full-length SIRT1; ex4, truncated inactive SIRT1 protein generated from the Sirt1 gene that lacks exon 4. * , protein that is distinct from the truncated SIRT1 protein and probably represents a splice variant of SIRT1 (see Supplementary Fig. S2d ). (b) Activity of signalling kinases p38 MAPK and AKT is important for oligodendrocyte generation from NSCs and neural progenitors. Proliferating Sirt1 lox / lox and NestinCre;Sirt1 lox/lox NSCs and neural progenitors were incubated with p38 MAPK inhibitor SB202190 (10 µM) or SB203580 (1 µM), PI(3)K inhibitor LY294002 (10 µM), AKT inhibitor MK-2206 (1 µm), MEK inhibitor U0126 (10 µm) or dimethylsulphoxide (DMSO) vehicle for 24 h. Cells were then switched to differentiation medium (1% FBS) containing the same concentration of compounds or vehicle and grown for a further 48 h. Cells were allowed to differentiate without added compounds for 5 more days, with complete medium changes every other day. Cells were stained for the oligodendrocyte marker O4. Left panel: mean±s.e.m. of the following number of independent experiments, n = 9 for control and dimethylsulphoxide; n = 5 for SB202190; n = 6 for LY294002; and n = 4 for U0126. Two-way ANOVA, compound, P < 0.0001; genotype, P < 0.0001; interaction, P = 0.0165; Bonferroni post-tests, * P < 0.05, * * P < 0.01. Right panel: mean ± s.e.m. of 4 independent experiments. Two-way ANOVA, compound, P = 0.0684; genotype, P = 0.0438, interaction, P = 0.0416; Bonferroni post-tests, * P < 0.05, * * P < 0.01. Uncropped images of blots are shown in Supplementary Fig. S8 .
be potentially used in regenerative medicine to enhance the generation of oligodendrocytes in vitro or in vivo.
DISCUSSION
Here we show that the conditional deletion of a gene in adult NSCs and neural progenitors influences OPC production in adults.
Our results also identify a new role for the protein deacetylase SIRT1 in normally limiting the expansion of OPCs as well as several cell types from SVZ NSCs and neural progenitors. Importantly, lack of active SIRT1 in adult NSCs and neural progenitors increases the pool of proliferating OPCs while maintaining their differentiation capacity, which could provide an effective approach to generate more oligodendrocytes to fight myelinating injury and diseases, including multiple sclerosis. Consistent with this possibility, SIRT1 inactivation ameliorates remyelination following demyelination and delays signs of paralysis in MOG -induced chronic EAE, a mouse model for multiple sclerosis [48] [49] [50] . Delayed paralysis may be due to enhanced remyelination in the brain and/or the spinal cord following SIRT1 inactivation, although loss of active SIRT1 in the nervous system might also diminish astrogliosis, minimize axonal damage and/or alter blood-brain barrier dynamics. Our findings contrast with the observation that SIRT1 inactivation in the whole body worsens EAE symptoms 59 , probably owing to the requirement of SIRT1 for T-cell tolerance. Thus, harnessing the benefits of SIRT1 inactivation for therapeutic purposes will probably require specific and transient targeting of the nervous system.
We also show that SIRT1 regulates OPC expansion at least in part by affecting signalling molecules downstream of PDGFRα-AKT and p38 MAPK-that have previously been implicated in OPC proliferation/survival at postnatal stages 55, 58 . We demonstrate that in adult NSCs and neural progenitors, signalling through AKT and p38 MAPK is critical for generating the oligodendrocyte lineage following SIRT1 inactivation, which may provide further strategies for manipulating the OPC pool in the adult brain. OPCs lacking active SIRT1 are able to give rise to mature oligodendrocytes, suggesting that increased PDGFRα signalling is transient. Our findings also suggest that SIRT1 affects Pdgfrα expression through direct action as a histone deacetylase at the Pdgfrα promoter. However, we cannot exclude other mechanisms for SIRT1 action. The changes in genes involved in cell metabolism and protein translation following SIRT1 inactivation may also mediate SIRT1 function on oligodendrocyte production, in particular as oligodendrocytes are highly metabolically active 1, 51 . The ability of SIRT1 to repress the production of OPCs from NSCs and neural progenitors without affecting oligodendrocyte differentiation contrasts with that of another sirtuin family member SIRT2, which acts to limit differentiation and maturation of oligodendrocytes from postnatal OPCs (ref. 13) . The role of SIRT1 in OPC expansion also contrasts with that of HDAC1/2, histone deacetylases that promote oligodendrocyte lineage progression by allowing oligodendrocyte-specific gene expression 12 . Thus, SIRT1 may act in concert with other lysine deacetylases to coordinate oligodendrocyte expansion and maturation. There exist relatively specific chemical inhibitors for SIRT1, SIRT2 and HDAC1/2 enzymes 60-62 , and we observed that the SIRT1-specific inhibitor EX-527 increases the production of oligodendrocytes from differentiating NSCs and neural progenitor cells in vitro. Therefore, combined inactivation of SIRT1 together with SIRT2 or HDAC1/2 may be particularly helpful for generating large pools of mature oligodendrocytes for therapeutic purposes.
Conversely, the role we identified for SIRT1 in normally limiting proliferation of NSCs and neural progenitors and the production of OPCs may also be important to prevent tumour formation 63 . Indeed, SIRT1 protein expression is downregulated in oligodendrogliomas and glioblastomas 64 . Chronic downregulation of SIRT1 in actively dividing OPCs, which have been proposed to be the cell of origin for oligodendrogliomas [65] [66] [67] [68] [69] , could increase the risk for deleterious mutations. Together, these results suggest that SIRT1 has functions in multiple tissues and that manipulating SIRT1 activity for therapeutic purposes may require cell type specificity. The function of SIRT1 to limit cell expansion may be beneficial to limit cancer, but may be detrimental for normal renewal and homeostasis during ageing or degenerative disease. This may explain why SIRT1-overexpressing mice have positive effects on metabolism at midlife, but do not exhibit extension of maximal lifespan 24, 70 . As SIRT1 inactivation is predicted to have both beneficial and detrimental effects, transient pulses of SIRT1 inactivation may be particularly helpful to generate new NSCs and neural progenitors and their progeny to fight brain injury without inducing long-term detrimental consequences. Together, our findings have important ramifications for the development of cellular or pharmacological therapies for myelin injuries and demyelinating diseases, such as multiple sclerosis.
METHODS
Methods and any associated references are available in the online version of the paper. Fig. S7b,c) . L.M.L.C. and S.J.B. generated and characterized the NestinCreER mice. All authors discussed the results and commented on the manuscript.
Animals. Sirt1 +/− and Sirt1
lox / lox mice in FVB/N and 129/Sv backgrounds, respectively, were generously provided by F. Alt (Harvard University, USA). NestinCre mice in a C57BL/6 background were purchased from Jackson Laboratories and were crossed with female Sirt1 lox / lox mice owing to inheritance of the transgene through the male germline. mT/mG mice 46 were also obtained from Jackson Laboratories and maintained on a 129/Sv background. NestinCreER T2 -IRES-hPLAP (abbreviated NestinCreER) mice expressing CreERT2 under the control of the rat Nestin promoter and second intron as a transgene were generated in the S.J.B. laboratory and maintained on a predominantly 129/Sv background 41, 42, 44 . All mice used for in vivo experiments were male. Primary cultures of NSC/progenitors were derived from a mixture of male and female mice (sex-matched between genotypes). Mice were maintained in the Stanford University Animal Facility. All care and procedures were in accordance with the Guide for the Care Fluorescence-conjugated secondary antibodies were obtained from Jackson ImmunoResearch and Molecular Probes. chronic EAE was performed as described previously 71 . Mice were scored by blinded investigators using the following guidelines: 0, no paralysis; 1, loss of tail tone; 2, hindlimb weakness; 3, hindlimb paralysis; 4, hindlimb and forelimb paralysis; 5, moribund or dead. The Mann-Whitney U -test was used for statistical analysis.
EAE. Induction of MOG
In vivo demyelination. Eight-week-old mice were anaesthetized with ketamine/xylazine solution (10 mg ml −1 ketamine; 1 mg ml −1 xylazine) and placed into a stereotactic injection apparatus. A hole was drilled in the skull to inject 1 µlof 1% lysolecithin solution (l-α-lysophosphatidylcholine) into the corpus callosum (0.5 mm anterior-posterior, 1.0 mm medial-lateral, −2.1 mm dorsal-ventral relative to bregma) using a 33-gauge Hamilton needle. Myelination was assessed by quantifying the coverage of fluorescent MBP staining in the injection region over background using Adobe Photoshop.
Tamoxifen treatment. A solution of 20 mg ml −1 tamoxifen (Sigma) was prepared in an ethanol/corn oil (1:9) mixture. Eight-week-old mice were injected intraperitoneally once daily for 3 days with vehicle or tamoxifen (0.225 mg g −1 mouse). A 20-day retention period was observed before NSC/tissue isolation. For fate analysis, 8-10-week-old mice were injected once with vehicle or tamoxifen (0.133 mg g −1 mouse) and perfused after 10 days. To quantify the density of mGFP-positive cells, 30 µm sections from bregma 0 mm to +1.15 mm were counted for mGFP-positive cells and normalized to the area. To assess the percentage of GFP-positive cells of a particular cell fate, Z -stacks containing the SVZ were assessed for cells that were positive for both GFP and the marker of interest.
In vivo proliferation and fate analysis. To quantify proliferation, 10-week-old mice were injected with EdU (50 mg kg −1 -Invitrogen) intraperitoneally for 2 h. The Invitrogen Click-It EdU Cell Proliferation Assay kit was used on every sixth coronal section (30 µm) from bregma −1.65 mm to +1.15 mm for the SVZ and from bregma −3.60 to −1.35 mm for the dentate gyrus according to manufacturer's instructions. Sections were counted for EdU-positive nuclei in the dentate gyrus granule cell layer (GCL) and subgranular zone (at the hilus/GCL border) and in the SVZ. The total number of EdU-positive nuclei per SVZ was estimated by multiplying the total number of EdU-positive nuclei by 6. The number of EdU-positive nuclei in the dentate gyrus was normalized to the GCL volume.
To assess the number and fate of cells near the SVZ, BrdU (50 mg kg −1 -Calbiochem or Sigma) was injected intraperitoneally into 8-week-old male mice daily for 7 days before perfusing on the eighth day. Coronal brain sections (40 µm) were stained for BrdU and NG2 as described below. To quantify the density of proliferating cells, sections from bregma 0 mm to +1.15 mm were counted for BrdUpositive cells in the striatum and septum and normalized to the area. To quantify the percentage of BrdU-positive cells of a particular fate, Z -stacks of sections were assessed for cells that were positive for both BrdU and the cell fate marker of interest.
Immunohistochemistry. Brains were processed for immunohistochemistry as described previously 72 . Heat-induced antigen retrieval was performed except in the case of NG2. Antibodies were diluted as follows: SIRT1 1:1,000, OLIG2 1:500, NG2 1:500, NeuN 1:600, GFAP 1:500, BrdU 1:400, Ki67 1:200, SOX2 1:200, DCX 1:200, MBP 1:500. BrdU staining was performed as described previously 72 . Immunostaining for alkaline phosphatase activity was performed with the Vector Blue Alkaline Phosphatase Substrate Kit III (#SK-5300 Vector Laboratories).
NSC and neural progenitor cultures. Isolation and propagation of adult mouse
NSCs/progenitors were performed as described previously 72 .
Postnatal OPC cultures. OPCs were isolated and cultured from postnatal day 7-8 mouse pups as described previously 73 . OPCs were cultured at 2,000 cells ml −1 in proliferation media (containing CNTF, PDGF-AA, NT-3) for 5 days or cultured at 10,000 cells ml −1 in proliferation media for 2 days and then placed in differentiation media (containing CNTF and T3 without PDGF-AA and NT-3) for 3 days. Antibodies were used at the following dilutions: NG2 1:400, CNPase: 1:100, MBP: 1:500, secondary 1:1,000. For EdU incorporation assays, proliferating and differentiating OPCs were incubated with 2.5 µM EdU for 4 h and 24 h, respectively, before staining using the Invitrogen Click-iT EdU staining kit.
Differentiation of NSCs and neural progenitors. Primary NSCs/progenitors
were dissociated and plated onto poly-d-lysine-coated coverslips overnight (50,000 cells ml −1 ). The following day, proliferation/self-renewal medium was replaced by differentiation medium: NeuroBasal-A medium with PSQ, serumfree B27 supplement without vitamin A, and 1% FBS. Differentiation medium was changed every other day. To examine the effect of kinase inhibitors on NSC/progenitor differentiation, primary NSCs/progenitors were dissociated and plated overnight (25,000 cells ml −1 ). The following day, half of the medium was replaced by fresh proliferation/self-renewal media (1× growth factors) containing 2× vehicle or compounds. Compounds were used at the following final concentrations: U0126 monoethanolate (Sigma #U120; 10 µM), LY294002 (EMD #440202; 10 µM), SB202190 (Sigma #S7067; 10 µM), EX-527 (BioVision; 5 µM), SB203580 (Selleck Chemicals; 1 µM), MK-2206 (Selleck Chemicals; 1 µM). Doses were chosen on the basis of published literature as well as the concentrations known to target these enzymes specifically. Twenty-four hours later, medium was replaced by differentiation medium containing 1× dimethylsulphoxide or compounds. Thereafter, medium was changed completely with differentiation medium (without vehicle or compounds) every other day.
Immunocytochemistry. Cells were fixed with 4% PFA/2% sucrose, permeabilized with PBS + 0.4% Triton X-100, and stained with antibodies diluted in 5% goat serum and 7.5% BSA in 1× PBS at the following concentrations: GFAP 1:1,000, MBP 1:500, NESTIN 1:200, SIRT1 1:1,000, Tuj1 1:1,000, fluorescence-conjugated secondary antibody 1:500. For O4 staining, unfixed cells were incubated with the antibody against O4 (1:1 in 10% goat serum/1% BSA/0.1M l-lysine) before fixation and secondary antibody staining. Coverslips were mounted using Vectashield solution containing DAPI (Vector Laboratories).
ChIP. NSCs and neural progenitors from 8-to 10-week-old mice were collected at early passage 3 and processed for ChIP as described previously 72 . Standard curves were determined for each primer set using a serial dilution of input chromatin and then used to calculate fold enrichment over the negative control gene HoxA10 (not expressed in NSCs and neural progenitors).
Primers: Pdgfrα forward, 5 -TTGTTGAAGTCTGGGGGTTG-3 ; Pdgfrα reverse, 5 -TCCCTAGGACTCCTTGCTCTC-3 ; HoxA10 forward, 5 -ATGTCAGCCAGAA-AGGGCTA-3 ; HoxA10 reverse, 5 -ATGAGCGAGTCGACCAAAAA-3 .
RT-qPCR. Total RNA from NSCs and neural progenitors was collected and purified using the Qiagen RNeasy kit and processed for RT-qPCR as described previously 72 . Primers: Pdgfrα forward, 5 -TCCATGCTAGACTCAGAAGTCA-3 ; Pdgfrα reverse, 5 -TCCCGGTGGACACAATTTTTC-3 ; Egfr forward, 5 -GCCATCCTGTCC-AACTATGG-3 ; Egfr reverse, 5 -GATGGGGTTGTTGCTGAATC-3 ; Fgfr1 forward, 5 -CGCAGACTTTGGCTTAGCTC-3 ; Fgfr1 reverse, 5 -GGTGTGTGTAGATCCG-GTCA-3 ; TrkC forward, 5 -GCCAGAGCCTTTACTGCATC-3 ; TrkC reverse, 5 -TGGCTCACACTGATCTCTGG-3 ; β-actin forward, 5 -TGTTACCAACTGGGA-CGACA-3 ; β-actin reverse, 5 -CTCTCAGCTGTGGTGGTGAA-3 .
Microarray. RNA from proliferating adult NSCs and neural progenitors at passage 2 was collected and purified using the Qiagen RNeasy kit. Samples were processed by
